Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07673744 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
A Phase 2 study, sponsored by TG Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT07673744 is a Phase 2 study that is actively recruiting participants, run by TG Therapeutics. The registered enrollment target is 120 participants.
The verdict
NCT07673744, a Phase 2 study, is actively recruiting participants, sponsored by TG Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
Interventions
- DRUG Placebo
- DRUG Ublituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2026-07-30 |
| Est. Completion | 2030-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07673744
The ClinicalTrials.gov registry entry for NCT07673744 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07673744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07673744 about?
NCT07673744 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)". The primary purpose of this study is to evaluate the efficacy of ublituximab in adult participants with MG responding to treatment with efgartigimod.
What is the current status of trial NCT07673744?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2026-07-30. Estimated completion is 2030-01-01.
What interventions are being tested in trial NCT07673744?
The interventions under investigation include: Placebo (DRUG), Ublituximab (DRUG).
Who is sponsoring clinical trial NCT07673744?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.